Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population
Open Access
- 22 August 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Hybrid Imaging
- Vol. 2 (1) , 1-13
Abstract
99mTechnetium-HDP (HDP) bone scans differentiate transthyretin (ATTR) cardiac amyloid from other infiltrative myocardial diseases. These scans are not quantitative and are assessed by comparing myocardial uptake to bone. This study examined whether quantitative HDP SPECT/CT can discriminate individuals with cardiac ATTR from the population without this disease. HDP thoracic xSPECT/CT QUANT (xQUANT) was performed in 29 patients: ATTR cardiac amyloid (n = 6); AL cardiac amyloid (n = 1); other infiltrative myocardial disease (n = 4); no known infiltrative cardiac disease (n = 18). SUVmax measured within volumes of interest for whole heart, ascending aorta blood pool, and specific bones. HDP myocardial uptake calculated as whole heart minus blood pool. The cardiac ATTR group had greater HDP myocardial uptake than those with no known infiltrative disease (p = 0.002). AL and other myocardial diseases had uptake indistinguishable from the group with no known infiltrative cardiac disease. The SUVmaxima were sufficiently similar between individuals without cardiac ATTR that a 99% reference interval for HDP uptake could be calculated, providing an upper limit cut point of SUVmax 1.2. Individuals with cardiac ATTR had SUVmax well above this cut point. Quantitative SPECT/CT can measure HDP myocardial uptake in individuals with normal hearts and those with cardiac ATTR without recourse to comparison with bone. It enables calculation of a reference interval for HDP myocardial uptake in the population without ATTR cardiac amyloid. Using this reference interval single individuals with cardiac ATTR can be accurately discriminated from the non-affected population. This technique uses a NIST traceable calibration source, potentially allowing development of multicentre clinical decision limits. Its role in disease management warrants further assessment.Keywords
This publication has 16 references indexed in Scilit:
- Nuclear imaging of cardiac amyloidosisJournal of Nuclear Cardiology, 2017
- Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of EchocardiographyEuropean Heart Journal - Cardiovascular Imaging, 2017
- Activity concentration measurements using a conjugate gradient (Siemens xSPECT) reconstruction algorithm in SPECT/CTNuclear Medicine Communications, 2016
- SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate.2016
- Usefulness of99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosisAmyloid, 2015
- Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modalityEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CTEJNMMI Research, 2013
- Tumor Quantification in Clinical Positron Emission TomographyTheranostics, 2013
- Determining Decision Limits for New Biomarkers: Clinical and Statistical ConsiderationsClinical Chemistry, 2011
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJACC, 2005